ClinicalTrials.gg
RecruitingNCT07562932ACTION-CSUpdated Oct 15, 2026

Assessing Catecholamine Treatment Initiation Options: Norepinephrine vs Dopamine for Cardiogenic Shock

An interventional study of Norepinephrine and Dopamine Agent in Cardiogenic Shock, sponsored by Chonnam National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Chonnam National University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 15, 2026Now RecruitingStart date moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
512
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Shock, Cardiogenic with a site in Korea, Republic of — 8 open to participants now, 8 under way, none of them phase 3. Shock, Cardiogenic · Korea, Republic of.

Planned enrollment
2nd of 10
512 · median 280
Started
2026
with 2 others
No phase
8 of 13
5 open now
Registered
12th of 13
by date
Lead sponsor
3 of 13
Chonnam National University Hospital

Among the 13 studies in Shock, Cardiogenic with a site in Korea, Republic of, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is one of 8 with no phase, and was the 12th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

8 of the 13 studies in Shock, Cardiogenic with a site in Korea, Republic of are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Shock, Cardiogenic with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The goal of this multicenter, open-label, randomized clinical trial is to learn whether norepinephrine or dopamine is more effective and safer as the first-line vasoactive drug for treating cardiogenic shock in adults. Cardiogenic shock is a life-threatening condition in which the heart cannot pump enough blood to supply the body. The main questions this study aims to answer are:

Does norepinephrine reduce the risk of death or worsening cardiogenic shock compared with dopamine?

Does norepinephrine lead to fewer complications such as arrhythmias, the need for mechanical circulatory support, or cardiac arrest?

Researchers will compare norepinephrine and dopamine to see which drug better stabilizes blood pressure, improves tissue perfusion, and prevents progression of shock during the early phase of treatment.

Participants will:

Be randomly assigned to receive either norepinephrine or dopamine as the first vasoactive drug

Receive treatment and monitoring based on current clinical guidelines for cardiogenic shock

Undergo regular assessments of blood pressure, laboratory values, heart rhythm, and organ function during hospitalization

Be followed for outcomes at 1 month, 6 months, and 1 year after enrollment

This study aims to provide evidence that will help determine which initial vasoactive drug offers better outcomes for patients with cardiogenic shock and guide future treatment recommendations.

Read the detailed description

Cardiogenic shock is a severe form of acute circulatory failure characterized by inadequate cardiac output, tissue hypoperfusion, and high short-term mortality. Despite advances in revascularization, mechanical circulatory support, and critical care management, early hemodynamic stabilization remains a major determinant of clinical outcomes. Vasoactive drugs are essential components of initial therapy, yet the optimal first-line agent for cardiogenic shock has not been definitively established.

Norepinephrine and dopamine are widely used vasoactive agents, but they may exert their effects through different physiological mechanisms. Their relative impact on vascular tone, cardiac output, and heart rate can vary depending on dose, patient characteristics, and the underlying pathophysiology of shock. Prior studies, including observational analyses and a landmark randomized trial, have suggested potential differences in safety profiles-particularly regarding arrhythmias-but these findings have not been confirmed in a contemporary population with standardized shock definitions and modern management strategies.

This multicenter, open-label, randomized clinical trial is designed to compare norepinephrine and dopamine as the initial vasoactive drug in adults with cardiogenic shock. The study uses a protocol-defined dosing algorithm to ensure consistent titration and incorporates current guideline-based management across participating centers. The primary endpoint evaluates both early hemodynamic deterioration and 28-day mortality, reflecting clinically meaningful outcomes during the most vulnerable phase of shock.

By enrolling a large, diverse population across multiple centers, this trial aims to provide definitive evidence regarding the comparative effectiveness and safety of norepinephrine versus dopamine as first-line therapy. The results are expected to inform clinical guidelines and support standardized treatment strategies for patients with cardiogenic shock.

03

Conditions studied

  • Cardiogenic Shock

Browse trials for

Keywords

  • Vasoactive drug
  • Norepinephrine
  • Dopamine
  • Randomized controlled trial
  • Cardiogenic shock
04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: 1\&2

  1. Age ≥ 19
  2. Cardiogenic shock (a) in the stage of Society for cardiovascular angiography and intervention (SCAI) C or D

    • Cardiogenic shock (a) was defined as follows, and should fulfill both 1) and 2)

      1. systolic blood pressure \<90 mm Hg for ≥30 min or need of inotropes or vasopressors to maintain systolic blood pressure >90 mm Hg And
      2. Impaired cardiac function confirmed by cardiac catheterization or echocardiography

        a Cardiogenic shock was defined as follows, and should fulfill both 1) and 2)

      <!-- -->

      1. systolic blood pressure \<90 mm Hg for ≥30 min or need of inotropes or vasopressors to maintain systolic blood pressure >90 mm Hg And
      2. Impaired cardiac function confirmed by cardiac catheterization or echocardiography
    • Cardiac index (CI) \< 2.2 L/min/m², measured by pulmonary artery catheter
    • LVEF \< 45% on echocardiography;
    • Right ventricular dysfunction, defined by one or more of: TAPSE \< 17 mm; S' \< 9.5 cm/sec; FAC \< 35%11; or visual estimation of RV wall motion abnormality.

Or Structural cardiac abnormality capable of causing cardiogenic shock, even if LV/RV systolic indices do not meet the thresholds above (examples, infarct ventricular septal rupture or severe valvular regurgitation)

Patients will be further classified based on the SCAI shock classification system12 as follows:

  • SCAI B: no signs of hypoperfusion
  • SCAI C: any signs of hypoperfusion, cardiogenic shock will be classified as SCAI C, and these include mental status change, cool and clammy skin, mottled skin appearance, decreased urine output (30ml/hour) or lactate over 2.0mmol/L
  • SCAI D: shock progression despite use of the index vasoactive agent at ≥75% of the predefined maximal dose
  • SCAI E: Impending arrest or overt circulatory collapse

Exclusion Criteria: any of these,

  1. Administration of vasoactive drug more than 6 hours before enrollment
  2. Receiving norepinephrine or dopamine at doses exceeding the protocol defined maximal dose at the time of enrollment.
  3. Receiving any vasoactive agent other than norepinephrine or dopamine
  4. Patients receiving a continuous infusion of both norepinephrine and dopamine
  5. Patients already on temporary mechanical circulatory supportb before enrollment
  6. Cardiogenic shock in the stage of SCAI E
  7. Glasgow Coma Scale lower than 8 or other evidence of irreversible brain injury
  8. Shock etiologies other than cardiogenic which include postcardiotomy shock or mixed shock
  9. Pregnancy or lactation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
512 participants (estimated)

Study arms

  • Experimental
    Norepinephrine First-Line Vasoactive Drug

    Participants assigned to this arm will receive norepinephrine as the first-line vasoactive drug for the treatment of cardiogenic shock. The drug will be initiated and titrated according to the protocol-defined dosing algorithm, with adjustments based on hemodynamic response, laboratory values, and clinical status. If participants were receiving vasoactive agents before randomization, norepinephrine will be started at an equivalent protocol-defined dose, and other agents will be tapered as clinically appropriate. All treatment and monitoring will follow current clinical guidelines for cardiogenic shock.

    Drug: Norepinephrine

  • Active comparator
    Dopamine First-Line Vasoactive Drug

    articipants assigned to this arm will receive dopamine as the first-line vasoactive drug for the treatment of cardiogenic shock. The drug will be initiated and titrated according to the protocol-defined dosing algorithm, with adjustments based on hemodynamic response, laboratory values, and clinical status. If participants were receiving vasoactive agents before randomization, dopamine will be started at an equivalent protocol-defined dose, and other agents will be tapered as clinically appropriate. All treatment and monitoring will follow current clinical guidelines for cardiogenic shock.

    Drug: Dopamine Agent

Interventions

  • Norepinephrine will be administered as an intravenous continuous infusion and used as the first-line vasoactive drug for the treatment of cardiogenic shock. The medication will be prepared in standard intensive care unit infusion bags and delivered through a controlled infusion pump. The infusion will be initiated and titrated according to a protocol-defined dosing algorithm, with adjustments based on blood pressure, hemodynamic response, laboratory values, and overall clinical assessment. If a participant was receiving vasoactive agents before randomization, norepinephrine will be started at an equivalent protocol-defined dose, and non-assigned agents will be tapered as clinically appropriate. The duration of infusion will depend on the participant's clinical stabilization. All administration and monitoring will follow current clinical guidelines for cardiogenic shock.

  • DrugDopamine Agent

    Dopamine will be administered as an intravenous continuous infusion and used as the first-line vasoactive drug for the treatment of cardiogenic shock. The medication will be prepared in standard intensive care unit infusion bags and delivered through a controlled infusion pump. The infusion will be initiated and titrated according to a protocol-defined dosing algorithm, with adjustments based on blood pressure, hemodynamic response, laboratory values, and overall clinical assessment. If a participant was receiving vasoactive agents before randomization, dopamine will be started at an equivalent protocol-defined dose, and non-assigned agents will be tapered as clinically appropriate. The duration of infusion will depend on the participant's clinical stabilization. All administration and monitoring will follow current clinical guidelines for cardiogenic shock.

06

What researchers measure

Primary outcomes

  1. A composite of 28-day all-cause death or signs of progressive or refractory cardiogenic shock within the first 24 hours

    signs of progressive or refractory cardiogenic shock within the first 24 hours, defined as follows, any of: * Sustained low blood pressure (mean arterial pressure \< 60mmHg) more than 30 minutes * Lactate over 4 mmol/L, higher than initial lactate level at 4 hours after randomization * Initiation of treatment with mechanical circulatory support * Initiation of second-line vasoactive drug * Cardiac arrest requiring cardiopulmonary resuscitation * Arrhythmia requiring electrical cardioversion \*\*For patients who experience more than one qualifying event, the primary endpoint will be determined based on the first event that occurs.

    Time frame: 28 days

Secondary outcomes

  1. All-cause death at 28th day

    Time frame: 28 days

  2. Cardiovascular death at 28th day

    Time frame: 28 days

  3. Number of participants who develop signs of progressive or refractory cardiogenic shock within the first 24 hours

    defined as follows, any of: * Sustained low blood pressure (mean arterial pressure \< 60mmHg) more than 30 minutes * Lactate over 4 mmol/L, higher than initial lactate level at 4 hours after randomization * Initiation of treatment with mechanical circulatory support * Initiation of second-line vasoactive drug * Cardiac arrest requiring cardiopulmonary resuscitation * Arrhythmia requiring electrical cardioversion

    Time frame: the first 24 hours

  4. Number of participants who initiate mechanical circulatory support within the first 24 hours

    Impella, ECMO or IABP

    Time frame: the first 24 hours

  5. Number of participants who initiate a second-line vasoactive drug within the first 24 hours

    Time frame: the first 24 hours

  6. Number of participants with cardiac arrest requiring cardiopulmonary resuscitation within the first 24 hours

    Time frame: the first 24 hours

  7. Number of participants with arrhythmia requiring electrical cardioversion within the first 24 hours

    Time frame: the first 24 hours

  8. Number of participants who receive cardiac replacement treatment (temporary or durable mechanical circulatory support or heart transplantation) within the first 28 days

    Temporary mechanical circulatory support include Impella, ECMO or IABP.

    Time frame: First 28 days

  9. Number of participants with first-time initiation of renal replacement therapy for acute kidney injury (AKI) during initial hospitalization

    Time frame: First 28 days

  10. Duration of vasoactive drug use (hours) during initial hospitalization

    Discontinuation of vasoactive drugs is defined as the point when they are no longer required for more than 24 hours and there is no recurrence of shock.

    Time frame: First 28 days

  11. Number of participants with new-onset or recurrent atrial or ventricular arrhythmia requiring pharmacologic or electrical cardioversion during initial hospitalization

    Time frame: First 28 days

  12. Number of participants who develop acute limb ischemia requiring surgical or interventional treatment during initial hospitalization

    Time frame: First 28 days

  13. Number of participants who develop ischemic or hemorrhagic stroke during initial hospitalization

    Time frame: First 28 days

  14. All-cause death at 1 year

    Time frame: 1 year

  15. Cardiovascular death at 1 year

    Time frame: 1 year

  16. Number of participants with rehospitalization due to heart failure within 1 year

    Time frame: 1 year

  17. Number of participants with first-time initiation of renal replacement therapy at 1 year

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. No abstract available. PubMed 34447992 ↗
  • Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018 Nov 13;138(20):e618-e651. doi: 10.1161/CIR.0000000000000617. No abstract available. PubMed 30571511 ↗
  • Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179-84. doi: 10.1159/000339789. Epub 2012 Aug 7. No abstract available. PubMed 22890468 ↗
  • Lansky AJ, Messe SR, Brickman AM, Dwyer M, van der Worp HB, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Moy CS, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. J Am Coll Cardiol. 2017 Feb 14;69(6):679-691. doi: 10.1016/j.jacc.2016.11.045. PubMed 28183511 ↗
  • Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW; Academic Research Consortium. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation. 2018 Jun 12;137(24):2635-2650. doi: 10.1161/CIRCULATIONAHA.117.029289. PubMed 29891620 ↗
  • Mathew R, Di Santo P, Hibbert B. Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock. Reply. N Engl J Med. 2021 Nov 25;385(22):2108-2109. doi: 10.1056/NEJMc2114890. No abstract available. PubMed 34818495 ↗
  • Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, Charron P, Corrado D, Dagres N, de Chillou C, Eckardt L, Friede T, Haugaa KH, Hocini M, Lambiase PD, Marijon E, Merino JL, Peichl P, Priori SG, Reichlin T, Schulz-Menger J, Sticherling C, Tzeis S, Verstrael A, Volterrani M; ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022 Oct 21;43(40):3997-4126. doi: 10.1093/eurheartj/ehac262. No abstract available. PubMed 36017572 ↗
  • Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, Lochen ML, Lumbers RT, Maesen B, Molgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, Kotecha D; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Sep 29;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176. No abstract available. PubMed 39210723 ↗
  • Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, Juni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Oct 12;44(38):3720-3826. doi: 10.1093/eurheartj/ehad191. No abstract available. PubMed 37622654 ↗
  • Rao SV, O'Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, Baber U, Baker H, Cohen MG, Cruz-Ruiz M, Davis LL, de Lemos JA, DeWald TA, Elgendy IY, Feldman DN, Goyal A, Isiadinso I, Menon V, Morrow DA, Mukherjee D, Platz E, Promes SB, Sandner S, Sandoval Y, Schunder R, Shah B, Stopyra JP, Talbot AW, Taub PR, Williams MS. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025 Apr;151(13):e771-e862. doi: 10.1161/CIR.0000000000001309. Epub 2025 Feb 27. PubMed 40014670 ↗
  • Gaies MG, Gurney JG, Yen AH, Napoli ML, Gajarski RJ, Ohye RG, Charpie JR, Hirsch JC. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med. 2010 Mar;11(2):234-8. doi: 10.1097/PCC.0b013e3181b806fc. PubMed 19794327 ↗
  • Naidu SS, Baran DA, Jentzer JC, Hollenberg SM, van Diepen S, Basir MB, Grines CL, Diercks DB, Hall S, Kapur NK, Kent W, Rao SV, Samsky MD, Thiele H, Truesdell AG, Henry TD. SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies: This statement was endorsed by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), American Heart Association (AHA), European Society of Cardiology (ESC) Association for Acute Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT), Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in December 2021. J Soc Cardiovasc Angiogr Interv. 2022 Jan 30;1(1):100008. doi: 10.1016/j.jscai.2021.100008. eCollection 2022 Jan-Feb. No abstract available. PubMed 39130139 ↗
  • Na SJ, Yang JH, Ko RE, Chung CR, Cho YH, Choi KH, Kim D, Park TK, Lee JM, Song YB, Choi JO, Hahn JY, Choi SH, Gwon HC. Dopamine versus norepinephrine as the first-line vasopressor in the treatment of cardiogenic shock. PLoS One. 2022 Nov 3;17(11):e0277087. doi: 10.1371/journal.pone.0277087. eCollection 2022. PubMed 36327286 ↗
  • De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL; SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010 Mar 4;362(9):779-89. doi: 10.1056/NEJMoa0907118. PubMed 20200382 ↗
  • Sinha SS, Morrow DA, Kapur NK, Kataria R, Roswell RO. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic Shock: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2025 Apr 29;85(16):1618-1641. doi: 10.1016/j.jacc.2025.02.018. Epub 2025 Mar 17. No abstract available. PubMed 40100174 ↗
  • van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, Kilic A, Menon V, Ohman EM, Sweitzer NK, Thiele H, Washam JB, Cohen MG; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Mission: Lifeline. Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. Circulation. 2017 Oct 17;136(16):e232-e268. doi: 10.1161/CIR.0000000000000525. Epub 2017 Sep 18. PubMed 28923988 ↗
  • Choi KH, Kang D, Park H, Park TK, Lee JM, Song YB, Hahn JY, Choi SH, Gwon HC, Cho J, Yang JH. In-hospital and long-term outcomes of cardiogenic shock complicating myocardial infarction versus heart failure. Eur J Heart Fail. 2024 Jul;26(7):1594-1603. doi: 10.1002/ejhf.3333. Epub 2024 Jun 10. PubMed 38855925 ↗
  • Osman M, Syed M, Patibandla S, Sulaiman S, Kheiri B, Shah MK, Bianco C, Balla S, Patel B. Fifteen-Year Trends in Incidence of Cardiogenic Shock Hospitalization and In-Hospital Mortality in the United States. J Am Heart Assoc. 2021 Aug 3;10(15):e021061. doi: 10.1161/JAHA.121.021061. Epub 2021 Jul 28. PubMed 34315234 ↗
  • Harjola VP, Lassus J, Sionis A, Kober L, Tarvasmaki T, Spinar J, Parissis J, Banaszewski M, Silva-Cardoso J, Carubelli V, Di Somma S, Tolppanen H, Zeymer U, Thiele H, Nieminen MS, Mebazaa A; CardShock Study Investigators; GREAT network. Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail. 2015 May;17(5):501-9. doi: 10.1002/ejhf.260. Epub 2015 Mar 28. PubMed 25820680 ↗
  • Ueki Y, Mohri M, Matoba T, Tsujita Y, Yamasaki M, Tachibana E, Yonemoto N, Nagao K. Characteristics and Predictors of Mortality in Patients With Cardiovascular Shock in Japan - Results From the Japanese Circulation Society Cardiovascular Shock Registry. Circ J. 2016;80(4):852-9. doi: 10.1253/circj.CJ-16-0125. Epub 2016 Mar 18. PubMed 27001192 ↗
  • Yang JH, Choi KH, Ko YG, Ahn CM, Yu CW, Chun WJ, Jang WJ, Kim HJ, Kim BS, Bae JW, Lee SY, Kwon SU, Lee HJ, Lee WS, Jeong JO, Park SD, Lim SH, Cho S, Park TK, Lee JM, Song YB, Hahn JY, Choi SH, Gwon HC. Clinical Characteristics and Predictors of In-Hospital Mortality in Patients With Cardiogenic Shock: Results From the RESCUE Registry. Circ Heart Fail. 2021 Jun;14(6):e008141. doi: 10.1161/CIRCHEARTFAILURE.120.008141. Epub 2021 Jun 15. PubMed 34129366 ↗
  • Gornik HL, Aronow HD, Goodney PP, Arya S, Brewster LP, Byrd L, Chandra V, Drachman DE, Eaves JM, Ehrman JK, Evans JN, Getchius TSD, Gutierrez JA, Hawkins BM, Hess CN, Ho KJ, Jones WS, Kim ESH, Kinlay S, Kirksey L, Kohlman-Trigoboff D, Long CA, Pollak AW, Sabri SS, Sadwin LB, Secemsky EA, Serhal M, Shishehbor MH, Treat-Jacobson D, Wilkins LR; Peer Review Committee Members. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jun 11;149(24):e1313-e1410. doi: 10.1161/CIR.0000000000001251. Epub 2024 May 14. PubMed 38743805 ↗

Related links

Individual participant data

Plan to share: No — ndividual participant data (IPD) will not be shared because of privacy considerations, regulatory requirements, and institutional policies governing the handling of sensitive clinical information. The study involves critically ill patients with cardiogenic shock, and sharing detailed participant-level data may pose risks to confidentiality. Only aggregated study results will be made publicly available.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2031, 59 months after the start.

Of 48 non-industry interventional studies with no phase under Shock, Cardiogenic, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 59 months is above that.

Counting every sponsor, half of 52 studies reached it within 39 months; a quarter within 24 and three quarters within 55.

Start moved once since we started tracking on Sep 25, 2026: May 2026 → Jun 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
May 1, 2026
StartActual
Jun 16, 2026was May 2026
Primary completionEst.
May 31, 2031
CompletionEst.
May 31, 2032
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
1 site added, 1 site removed
Show site
  • Chonnam National University Hospital · Gwangju, South Korea
Show 1 removed
  • Chonnam National University Hospital · Gwangju, South Korea
Oct 15, 2026
Start date
May 31, 2026→Jun 16, 2026 (actual)
Oct 15, 2026
Eligibility
3 criteria edited, 14 added, 1 removed
What changed in the criteria
  • EditedCardiogenic shockashock (a) in the stage of Society for cardiovascular angiography and intervention (SCAI) C or D
  • AddedCardiogenic shock (a) was defined as follows, and should fulfill both 1) and 2)
  • Editeda Cardiogenic shock was defined as follows, and should fulfill both 1) and 2)
  • Added<!-- -->
  • Addedsystolic blood pressure <90 mm Hg for ≥30 min or need of inotropes or vasopressors to maintain systolic blood pressure >90 mm Hg And
  • AddedImpaired cardiac function confirmed by cardiac catheterization or echocardiography
  • AddedCardiac index (CI) < 2.2 L/min/m², measured by pulmonary artery catheter
  • AddedLeft ventricular ejection fraction LVEF < 45% on echocardiography;
  • AddedRight ventricular dysfunction, defined by one or more of: TAPSE < 17 mm; S' < 9.5 cm/sec; FAC < 35%11; or visual estimation of RV wall motion abnormality.
  • AddedOr Structural cardiac abnormality capable of causing cardiogenic shock, even if LV/RV systolic indices do not meet the thresholds above (examples, infarct ventricular septal rupture or severe valvular regurgitation)
  • EditedPatients will be further classified based on the SCAI shock classification systemsystem12 as follows:
  • RemovedSCAI D: requirement of second-line vasoactive drug or mechanical circulatory support based on the predefined treatment protocol
  • AddedSCAI D: shock progression despite use of the index vasoactive agent at ≥75% of the predefined maximal dose
  • AddedSCAI E: Impending arrest or overt circulatory collapse
  • AddedReceiving norepinephrine or dopamine at doses exceeding the protocol defined maximal dose at the time of enrollment.
  • AddedReceiving any vasoactive agent other than norepinephrine or dopamine
  • AddedPatients receiving a continuous infusion of both norepinephrine and dopamine
  • AddedCardiogenic shock in the stage of SCAI E
Oct 15, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionA composite of 28-day all-cause death or signs of progressive or refractory cardiogenic shock within the first 24 hours: how it is measured was reworded
Oct 15, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionNumber of participants who develop signs of progressive or refractory cardiogenic shock within the first 24 hours: how it is measured was reworded
Oct 15, 2026
Contact
Study contact's phone or email changed: •••2643→•••4770; •••3392→•••4770. See the current contact
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    1 site added, 1 site removed
    Show site
    • Chonnam National University Hospital · Gwangju, South Korea
    Show 1 removed
    • Chonnam National University Hospital · Gwangju, South Korea
    Start date May 31, 2026→Jun 16, 2026 (now actual)
    Eligibility 3 criteria edited, 14 added, 1 removed
    What changed in the criteria
    • EditedCardiogenic shockashock (a) in the stage of Society for cardiovascular angiography and intervention (SCAI) C or D
    • AddedCardiogenic shock (a) was defined as follows, and should fulfill both 1) and 2)
    • Editeda Cardiogenic shock was defined as follows, and should fulfill both 1) and 2)
    • Added<!-- -->
    • Addedsystolic blood pressure <90 mm Hg for ≥30 min or need of inotropes or vasopressors to maintain systolic blood pressure >90 mm Hg And
    • AddedImpaired cardiac function confirmed by cardiac catheterization or echocardiography
    • AddedCardiac index (CI) < 2.2 L/min/m², measured by pulmonary artery catheter
    • AddedLeft ventricular ejection fraction LVEF < 45% on echocardiography;
    • AddedRight ventricular dysfunction, defined by one or more of: TAPSE < 17 mm; S' < 9.5 cm/sec; FAC < 35%11; or visual estimation of RV wall motion abnormality.
    • AddedOr Structural cardiac abnormality capable of causing cardiogenic shock, even if LV/RV systolic indices do not meet the thresholds above (examples, infarct ventricular septal rupture or severe valvular regurgitation)
    • EditedPatients will be further classified based on the SCAI shock classification systemsystem12 as follows:
    • RemovedSCAI D: requirement of second-line vasoactive drug or mechanical circulatory support based on the predefined treatment protocol
    • AddedSCAI D: shock progression despite use of the index vasoactive agent at ≥75% of the predefined maximal dose
    • AddedSCAI E: Impending arrest or overt circulatory collapse
    • AddedReceiving norepinephrine or dopamine at doses exceeding the protocol defined maximal dose at the time of enrollment.
    • AddedReceiving any vasoactive agent other than norepinephrine or dopamine
    • AddedPatients receiving a continuous infusion of both norepinephrine and dopamine
    • AddedCardiogenic shock in the stage of SCAI E
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionA composite of 28-day all-cause death or signs of progressive or refractory cardiogenic shock within the first 24 hours: how it is measured was reworded
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionNumber of participants who develop signs of progressive or refractory cardiogenic shock within the first 24 hours: how it is measured was reworded
    Contact Study contact's phone or email changed: •••2643→•••4770; •••3392→•••4770. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07562932
Lead sponsor
Chonnam National University Hospital
Responsible party
Min Chul Kim (Professor, MD, PhD, Chonnam National University Hospital) — Principal investigator
First posted
May 1, 2026
Start date
Jun 16, 2026
Primary completion
May 31, 2031 (estimated)
Completion
May 31, 2032 (estimated)
Last update
Oct 15, 2026

Study contacts

Min Chul Kim, Professor, MD, PhD
Contact
kmc3242@hanmail.net
820622204770
Yongwhan Lim, Professor, MD
Contact
kalmiarmfl@naver.com
820622204770
Min Chul Kim, Professor, MD, PhD
principal investigator · Chonnam National University Hospital
Min Chul Kin, Professor, MD, PhD
study chair · Chonnam National University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Norepinephrine

Start the discussion